We are live on ! Find out more
TBPH icon

Theravance Biopharma
TBPH

118 hedge funds and large institutions have $775M invested in Theravance Biopharma in 2020 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 51 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.35% less ownership

Funds ownership: 83.95% → 82.6% (-1.4%)

6% less funds holding

Funds holding: 125 → 118 (-7)

16% less call options, than puts

Call options by funds: $877K | Put options by funds: $1.04M

29% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 51

30% less capital invested

Capital invested by funds: $1.11B → $775M (-$336M)

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
118
Holders Change
-7
Holders Change %
-5.6%
% of All Funds
2.38%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
36
Reduced
51
Closed
18
Calls
$877K
Puts
$1.04M
Net Calls
-$162K
Net Calls Change
+$825K

Top Buyers

1
O
OrbiMed
New York
+$68.6M
2
CAM
Cormorant Asset Management
Massachusetts
+$10.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$4.59M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$2.62M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.91M

Top Sellers

1
Jane Street
Jane Street
New York
-$22.4M
2
Ameriprise
Ameriprise
Minnesota
-$19.6M
3
BG
Baupost Group
Massachusetts
-$10.8M
4
RCMNY
Rubric Capital Management (New York)
New York
-$7.41M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$5.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$140M +$1.2M +64,092 +0.7%
BG
2
Baupost Group
Massachusetts
$129M -$10.8M -574,000 -6%
O
3
OrbiMed
New York
$92M +$68.6M +3,664,640 +143%
Wellington Management Group
4
Wellington Management Group
Massachusetts
$69.9M +$4.59M +244,815 +5%
Vanguard Group
5
Vanguard Group
Pennsylvania
$67.6M -$2.31M -123,496 -3%
BlackRock
6
BlackRock
New York
$63.9M -$1.1M -58,493 -1%
C
7
Chescapmanager
Maryland
$17.1M +$1.12M +60,000 +5%
State Street
8
State Street
Massachusetts
$16.1M -$265K -14,147 -1%
Norges Bank
9
Norges Bank
Norway
$14.9M -$4.63M -247,064 -20%
RSCM
10
Rock Springs Capital Management
Maryland
$12.2M -$78.7K -4,200 -0.5%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$10.9M +$312K +16,662 +2%
Adage Capital Partners
12
Adage Capital Partners
Massachusetts
$10.3M -$5.15M -275,000 -28%
CAM
13
Cormorant Asset Management
Massachusetts
$9.61M +$10.3M +550,072 +550%
Northern Trust
14
Northern Trust
Illinois
$8.93M -$555K -29,626 -5%
Jacobs Levy Equity Management
15
Jacobs Levy Equity Management
New Jersey
$8.72M +$1.91M +101,829 +21%
RCMNY
16
Rubric Capital Management (New York)
New York
$8.14M -$7.41M -395,710 -42%
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$8.05M +$373K +19,919 +4%
Ameriprise
18
Ameriprise
Minnesota
$6.77M -$19.6M -1,044,830 -70%
PCM
19
Peregrine Capital Management
Minnesota
$6.1M -$737K -39,361 -9%
Hudson Bay Capital Management
20
Hudson Bay Capital Management
Connecticut
$4.73M +$2.62M +140,000 +78%
Goldman Sachs
21
Goldman Sachs
New York
$4.66M -$352K -18,780 -6%
Charles Schwab
22
Charles Schwab
California
$4.64M -$12.1K -646 -0.2%
TCM
23
Tekla Capital Management
Massachusetts
$4.41M +$1.3M +69,634 +30%
Wells Fargo
24
Wells Fargo
California
$4.09M -$80.8K -4,313 -2%
Deutsche Bank
25
Deutsche Bank
Germany
$3.87M -$4.13M -220,279 -46%
1
2 3 4 5

TBPH Hedge Fund Activity: Q3 2020 in Review

118 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2020, worth a combined $775M — down 30% from $1.11B a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of TBPH and 12 opened new positions — a net loss of 6 holders — while 51 trimmed existing stakes and 36 added.

The largest buyer was OrbiMed, adding an estimated $68.6M. The largest seller was Jane Street, cutting an estimated $22.4M.

  • 118 institutional investors held Theravance Biopharma (TBPH) as of Q3 2020, down from 125 in Q2 2020.
  • Funds reported $775M of Theravance Biopharma stock for Q3 2020, down 30% quarter-over-quarter.
  • 12 funds opened new Theravance Biopharma positions in Q3 2020 and 18 closed out, a net change of -6 holders.
  • The largest Theravance Biopharma buyer in Q3 2020 was OrbiMed, an estimated $68.6M added.
  • The largest Theravance Biopharma seller in Q3 2020 was Jane Street, an estimated $22.4M sold.

Based on aggregated 13F filings for Q3 2020.